Girentuximab-Zr-89

锆[89Zr]吉伦妥昔单抗

Report date: 2026/03/16 20:01:47

Base Information

Drug NameGirentuximab-Zr-89
Drug Alias Name吉非替康-Zr-89Zirconium-89 girentuximab锆[89Zr]-吉瑞昔单抗Zr-89-girentuximab89Zr-girentuximab +[15] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Zirconium > 89Zr +[4] 
Mechanisms of ActionPositron-emission tomography enhancersCarbonic anhydrase IX inhibitors
TargetsCarbonic anhydrase IX
Therapy Area/IndicationsContrast agentsvon Hippel-Lindau DiseaseUrinary Bladder Neoplasms +[20] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[9] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesWilex AG
China Registration ClassN/A

Develop Information

Active CompaniesTelix PharmaceuticalTelix International Pty LtdTelix Pharmaceuticals (Innovations) Pty Ltd +[8] 
Inactive CompaniesRadboud University Medical Center
Active IndicationsContrast agentsUrinary Bladder NeoplasmsTriple Negative Breast Neoplasms +[5] 
Inactive Indicationsvon Hippel-Lindau DiseaseUterine Cervical NeoplasmsSmall Cell Lung Carcinoma +[15] 

Other Information

ATC CodeN/A
Related LinksN/A